OBJECTIVE: To identify risk factors for endometrial cancer after benign results of endometrial biopsy or dilation and curettage (D&C). METHODS: Nested case-control study from Rochester Epidemiology Project data. Among 370 Olmsted County, Minnesota, residents who received an endometrial cancer diagnosis between 1970 and 2008, we identified 90 patients (24.5%) who had previous benign endometrial biopsy or D&C results (no atypical hyperplasia). We compared them with 172 matched control group participants who had benign endometrial biopsy or D&C results without subsequent endometrial cancer. RESULTS: Using a multivariable conditional logistic regression model, we found that oral contraceptive pill (OCP) use was protective (odds ratio [OR] 0.18, 95% CI [CI] 0.08-0.45; P<.001), and personal history of colorectal cancer (OR 4.44, 95% CI 1.02-19.31; P<.05), endometrial polyp (OR 4.12, 95% CI 1.40-12.17; P=.01), and morbid obesity (OR 3.40, 95% CI 1.18-9.78; P<.03) were independently associated with subsequent endometrial cancer. Compared with the presence of no risk factor, presence of one and two or more risk factors increased the risk of endometrial cancer by 8.12 (95% CI 3.08-21.44) and 17.87 (95% CI 5.57-57.39) times, respectively. Assuming a 2.6% lifetime risk of endometrial cancer, ORs of 8.12 and 17.87 for one and two or more of the four aforementioned risk factors confer a lifetime risk of approximately 18% and 32%, respectively. CONCLUSION: One fourth of patients with endometrial cancer had previous benign endometrial biopsy or D&C results. Personal history of colorectal cancer, presence of endometrial polyps, and morbid obesity are the strongest risk factors for having endometrial cancer after a benign endometrial biopsy or D&C result, and OCP use is the strongest protective factor. LEVEL OF EVIDENCE: II.
OBJECTIVE: To identify risk factors for endometrial cancer after benign results of endometrial biopsy or dilation and curettage (D&C). METHODS: Nested case-control study from Rochester Epidemiology Project data. Among 370 Olmsted County, Minnesota, residents who received an endometrial cancer diagnosis between 1970 and 2008, we identified 90 patients (24.5%) who had previous benign endometrial biopsy or D&C results (no atypical hyperplasia). We compared them with 172 matched control group participants who had benign endometrial biopsy or D&C results without subsequent endometrial cancer. RESULTS: Using a multivariable conditional logistic regression model, we found that oral contraceptive pill (OCP) use was protective (odds ratio [OR] 0.18, 95% CI [CI] 0.08-0.45; P<.001), and personal history of colorectal cancer (OR 4.44, 95% CI 1.02-19.31; P<.05), endometrial polyp (OR 4.12, 95% CI 1.40-12.17; P=.01), and morbid obesity (OR 3.40, 95% CI 1.18-9.78; P<.03) were independently associated with subsequent endometrial cancer. Compared with the presence of no risk factor, presence of one and two or more risk factors increased the risk of endometrial cancer by 8.12 (95% CI 3.08-21.44) and 17.87 (95% CI 5.57-57.39) times, respectively. Assuming a 2.6% lifetime risk of endometrial cancer, ORs of 8.12 and 17.87 for one and two or more of the four aforementioned risk factors confer a lifetime risk of approximately 18% and 32%, respectively. CONCLUSION: One fourth of patients with endometrial cancer had previous benign endometrial biopsy or D&C results. Personal history of colorectal cancer, presence of endometrial polyps, and morbid obesity are the strongest risk factors for having endometrial cancer after a benign endometrial biopsy or D&C result, and OCP use is the strongest protective factor. LEVEL OF EVIDENCE: II.
Authors: M Aarnio; R Sankila; E Pukkala; R Salovaara; L A Aaltonen; A de la Chapelle; P Peltomäki; J P Mecklin; H J Järvinen Journal: Int J Cancer Date: 1999-04-12 Impact factor: 7.396
Authors: Cornelia L Trimble; James Kauderer; Richard Zaino; Steven Silverberg; Peter C Lim; James J Burke; David Alberts; John Curtin Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Wilma L Lingle; Amy C Degnim; Karthik Ghosh; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; David W Hillman; Vera J Suman; Jo Johnson; Cassann Blake; Thea Tlsty; Celine M Vachon; L Joseph Melton; Daniel W Visscher Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: F Parazzini; E Negri; C La Vecchia; G Benzi; F Chiaffarino; A Polatti; S Francheschi Journal: Int J Cancer Date: 1998-06-10 Impact factor: 7.396
Authors: Jamie N Bakkum-Gamez; Nicolas Wentzensen; Matthew J Maurer; Kieran M Hawthorne; Jesse S Voss; Trynda N Kroneman; Abimbola O Famuyide; Amy C Clayton; Kevin C Halling; Sarah E Kerr; William A Cliby; Sean C Dowdy; Benjamin R Kipp; Andrea Mariani; Ann L Oberg; Karl C Podratz; Viji Shridhar; Mark E Sherman Journal: Gynecol Oncol Date: 2015-02-10 Impact factor: 5.482
Authors: Nicolas Wentzensen; Jamie N Bakkum-Gamez; J Keith Killian; Joshua Sampson; Richard Guido; Andrew Glass; Lisa Adams; Patricia Luhn; Louise A Brinton; Brenda Rush; Lori d'Ambrosio; Munira Gunja; Hannah P Yang; Montserrat Garcia-Closas; James V Lacey; Jolanta Lissowska; Karl Podratz; Paul Meltzer; Viji Shridhar; Mark E Sherman Journal: Int J Cancer Date: 2014-03-31 Impact factor: 7.396
Authors: Naomi S Clement; Thomas R W Oliver; Hunain Shiwani; Juliane R F Saner; Caroline A Mulvaney; William Atiomo Journal: BMJ Open Date: 2016-08-16 Impact factor: 2.692